| Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa. | |
| | |
MedLine Citation:
|
PMID: 21625417 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Bypassing agents are the mainstay of treatment for patients with hemophilia with high-titer inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding episodes in this population, timely administration of bypassing agents continues to be hampered by a number of practical limitations, including the need for refrigerated storage of the agent and its reconstitution at room temperature prior to administration, among others. In this review, the importance of early treatment of bleeds and factors that influence this more timely therapeutic approach are highlighted, together with the advantages offered by the use of a new formulation of recombinant activated factor VII that permits improved storage and portability, potentially optimizing timely bypassing agent administration. |
| | |
Authors:
|
Linda Butros; Koh Boayue; Prasad Mathew |
Related Documents
:
|
21594637 - Strong authentication scheme for telecare medicine information systems. 2291127 - Pharmaceutical service delivery by community pharmacies in areas of contrasting medical... 18590087 - Enhance your technology and enrich your bottom line. 8472767 - Shigellosis due to occupational contact with non-human primates. 21152457 - Management of hepatitis b: a longitudinal national survey - impact of the canadian hepa... 16634337 - Why physical medicine, physical disability and physical rehabilitation? we should aband... |
Publication Detail:
|
Type: Journal Article Date: 2011-05-12 |
Journal Detail:
|
Title: Drug design, development and therapy Volume: 5 ISSN: 1177-8881 ISO Abbreviation: Drug Des Devel Ther Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-05-31 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101475745 Medline TA: Drug Des Devel Ther Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 275-82 Citation Subset: IM |
Affiliation:
|
The University of New Mexico, Albuquerque, New Mexico, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Development of oral immunomodulatory agents in the management of multiple sclerosis.
Next Document: Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitu...